XML 44 R28.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Summary of Significant Accounting Policies |
Schedule of research and development costs | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended | ​ | Year Ended | ​ | ​ | Year Ended
​ |  | December 31, 2024 |  | December 31, 2023 |  | December 31, 2022
​ | ​ | (In thousands)
Barzolvolimab/Anti-KIT Program |  | $ | 123,750 |  | $ | 79,913 | ​ | $ | 51,220
CDX-622 | ​ |  | 17,341 | ​ |  | 16,299 | ​ |  | 5,613
CDX-585 | ​ |  | 2,813 | ​ |  | 6,357 | ​ |  | 9,793
Other Programs (a) | ​ |  | 19,646 | ​ |  | 15,442 | ​ |  | 15,632
Total R&D Expense | ​ | $ | 163,550 | ​ | $ | 118,011 | ​ | $ | 82,258
​ (a) Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended | ​ | Year Ended | ​ | Year Ended
​ |  | December 31, 2024 |  | December 31, 2023 |  | December 31, 2022
​ | ​ | (In thousands)
Personnel |  | $ | 51,906 |  | $ | 40,121 |  | $ | 32,674
Laboratory Supplies | ​ |  | 5,611 | ​ |  | 5,358 | ​ |  | 6,310
Facility | ​ |  | 5,094 | ​ |  | 4,970 | ​ |  | 4,764
Product Development (b) | ​ |  | 90,604 | ​ |  | 59,319 | ​ |  | 32,156
Other Expenses (c) | ​ |  | 10,335 | ​ |  | 8,243 | ​ |  | 6,354
Total R&D Expense | ​ | $ | 163,550 | ​ | $ | 118,011 | ​ | $ | 82,258
​ (b) Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing. (c) Other expenses primarily include research and development consulting, insurance, licensing and software expenses.
Schedule of potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
Stock options | ​ | 7,540,109 | ​ | 6,378,924 | ​ | 5,085,662

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration